Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

Part of paid clinical trials in San Francisco, California.

Sponsor
University of Alberta
Study ID
NCT03193151
Status
Recruiting

Conditions

  • Liver Dysfunction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liver biopsy — PROCEDURE
    5 mm fragment of liver transplant biopsy taken for clinical indication

Study Details

INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.

Key Dates

Start date
Dec 19, 2017
Status verified
Jun 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
300 participants (estimated)

Primary Outcome Measure

Assign molecular scores (probability) of T cell mediated rejection, antibody mediated rejection in liver transplant biopsies, in a reference set of 100 biopsies [ Time Frame: two years ]

Central Contacts

Locations (8)

Find similar trials in San Francisco, CA

Related Studies